Provided by Tiger Trade Technology Pte. Ltd.

Alnylam Pharmaceuticals

445.12
+15.323.56%
Post-market: 445.12-0.1240-0.03%18:14 EST
Volume:908.16K
Turnover:402.50M
Market Cap:58.81B
PE:1.35K
High:447.69
Open:432.87
Low:430.27
Close:429.80
52wk High:495.55
52wk Low:205.87
Shares:132.11M
Float Shares:126.15M
Volume Ratio:0.79
T/O Rate:0.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3299
EPS(LYR):-2.1790
ROE:32.73%
ROA:3.65%
PB:251.42
PE(LYR):-204.27

Loading ...

A Look at Alnylam Pharmaceuticals's Valuation Following Raised Sales Guidance on Vutrisiran Outperformance

Simply Wall St.
·
4 hours ago

Alnylam Pharmaceuticals CSO Kevin Fitzgerald Reports Disposal of Common Shares

Reuters
·
Nov 20

Alnylam Pharmaceuticals (ALNY): Assessing Valuation Following Positive HELIOS-B Data on Vutrisiran Efficacy

Simply Wall St.
·
Nov 18

Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker

Benzinga
·
Nov 12

Alnylam Pharmaceuticals Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
Nov 11

Piper Sandler Remains a Buy on Alnylam Pharma (ALNY)

TIPRANKS
·
Nov 10

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alnylam Pharma (ALNY) and Insulet (PODD)

TIPRANKS
·
Nov 10

Alnylam announces results from post hoc analyses of HELIOS-B Phase 3 study

TIPRANKS
·
Nov 10

BRIEF-Alnylam Pharmaceuticals Inc Says Amyloid Regression In 22% Of Vutrisiran-Treated Patients

Reuters
·
Nov 09

Alnylam Pharmaceuticals Inc - Amyloid Regression in 22% of Vutrisiran-Treated Patients

THOMSON REUTERS
·
Nov 09

Biotech stocks are coming back. Here's what's driving the sector higher.

Dow Jones
·
Nov 09

Alnylam Pharmaceuticals to Present at UBS Global Healthcare Conference

Reuters
·
Nov 04

Royalty Pharma Buys $310 Million AMVUTTRA Royalty from Blackstone

Reuters
·
Nov 04

Biotech Stocks Are Coming Back. Here's What's Driving The Sector Higher.

Dow Jones
·
Nov 04

Stock Track | Alnylam Pharmaceuticals Plummets 5% as Goldman Sachs Removes It from US Conviction List

Stock Track
·
Nov 03

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Dow Jones
·
Nov 03

Alnylam removed from US Conviction List at Goldman Sachs

TIPRANKS
·
Nov 03

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Benzinga_recent_news
·
Nov 02

Alnylam Pharmaceuticals Reports Strong TTR Growth Amid Challenges

TIPRANKS
·
Nov 01

Alnylam Pharmaceuticals Launches Promising Phase 3 Study on Nucresiran for hATTR-PN

TIPRANKS
·
Nov 01